- BNF:
- 13.9
- Status:
- Grey, Grey - after consultant/specialist recommendation
- Decision Date:
- None
Comments
GREY specialist recommendation : as per NHSE Service spec: Gender Identity Services for Adults. This should be done in close collaboration with the specialists at the Gender Identity Clinics. (Decision date - July 2023)
GREY: for facial hirsutism in women (decision date - Dec 2015, Nov 2019). Before considering eflornithine cream:
- Women who are overweight or obese should be encouraged to lose weight
- Check underlying cause as hirsutism may result from serious medical conditions or from medications (e.g. ciclosporin, glucocorticoids or minoxidil)
- The primary option for the majority of women with hirsutism is self-funded cosmetic treatments for reduction of hair growth or removal (e.g. shaving, plucking, laser treatment or electrolysis)
- Eflornithine should only be considered for use in women after failures of self-care and lifestyle measures, where alternative drug therapy e.g. co-cyprindiol, is ineffective, not recommended, contra-indicated or considered inappropriate.
- Treatment with eflornithine does not remove hairs but slows down hair growth such that users require less frequent hair removal by other methods
- Treatment should be discontinued if no effects are seen within 4 months
Grey Drug Classifications
- 1: Lack of data on effectiveness compared with standard therapy
- 5: Less cost-effective than current standard therapy
Grey Drug Classifications
- 1: Lack of data on effectiveness compared with standard therapy
- 5: Less cost-effective than current standard therapy
search again